Ibuprofen and Naproxen on a GLP-1: Is There an Interaction?

Ibuprofen and naproxen are the most common over-the-counter painkillers, and GLP-1 drugs are now taken by millions of people who also get headaches, period pain and sore knees. The good news first: there is no known direct interaction between the two. Neither drug changes how the other is broken down. What does change is timing. GLP-1 drugs slow how fast your stomach empties ^[1], and an NSAID tablet that sits in the stomach longer has longer to do what NSAIDs do to the stomach lining. That is the whole of the concern, and it is manageable rather than disqualifying.

The honest summary

• No pharmacological interaction is described. GLP-1 drugs act on the incretin system; NSAIDs block COX enzymes. They do not compete for the same liver pathways, and no GLP-1 label lists NSAIDs as an interacting drug class.
• The real mechanism is delayed gastric emptying. Slowing gastric emptying is part of how these drugs work, and it is measurable ^{[1] [2]}. A tablet that would normally clear the stomach in an hour may linger.
• NSAIDs carry their own well-quantified stomach risk. A meta-analysis of 280 placebo-controlled trials found NSAIDs roughly double the rate of upper gastrointestinal complications — perforation, obstruction or bleeding ^[4]. That risk exists with or without a GLP-1.
• Individual NSAIDs differ a lot. Ibuprofen at low doses sits at the safer end and piroxicam and ketorolac at the riskier end ^[5]. Which NSAID you choose matters more than whether you are on a GLP-1.
• Real-world data has not shown a spike in GI events. In a cohort of people with inflammatory bowel disease — a group with an already-irritable gut — starting a GLP-1 did not increase ileus, obstruction, bowel surgery or hospitalization compared with the year before ^[6].

What slowed gastric emptying actually does

Every GLP-1 drug slows gastric emptying to some degree, and that is not a side effect so much as part of the mechanism: food leaves the stomach more slowly, you feel full for longer, and the post-meal glucose spike is blunted ^[1]. A 2024 review in the Journal of Clinical Endocrinology & Metabolism looked at what happens when that effect becomes clinically relevant. Its most concrete finding is that retained stomach contents show up more often at upper endoscopy in people taking these drugs, though that rarely progresses to anything serious ^[1].

Two details from that review matter for anyone taking tablets. First, the effect is subject to tachyphylaxis — it fades with continued treatment, so the slowdown is most pronounced early on and after a dose increase. Second, in people whose stomach was already emptying slowly before treatment, the additional effect is limited ^[1]. So the window of greatest caution is the first weeks on a dose, not month eight.

Why that matters for an NSAID specifically

NSAIDs damage the stomach two ways: directly, by contacting the mucosa, and systemically, by blocking the prostaglandins that maintain the protective mucus layer. The systemic route is the dominant one, which is why enteric coating helps less than people expect. But contact time is not irrelevant, and a tablet that sits in a slowly-emptying stomach has more of it.

The size of the baseline risk is worth stating plainly, because it is the part people underestimate. The Coxib and traditional NSAID Trialists' meta-analysis pooled 280 trials against placebo and 474 head-to-head trials, covering more than 350,000 participants, and found that NSAIDs roughly doubled upper gastrointestinal complications ^[4]. That is the number to weigh, and it applies whether or not you take a GLP-1.

Not all NSAIDs carry the same risk

A systematic review of individual NSAIDs and upper gastrointestinal complications found a wide spread between agents rather than a single class effect ^[5]. Low-dose ibuprofen consistently appears at the lower-risk end; several older agents sit well above it. If you need an NSAID regularly while on a GLP-1, the choice of agent and the dose are the levers with the most evidence behind them.

Acetaminophen (paracetamol) is worth mentioning as the obvious alternative, since it does not carry the NSAID gastric risk at all. It is also, separately, the drug most often used to measure gastric emptying in research, precisely because its absorption tracks how fast the stomach empties. On a GLP-1 you may notice it takes longer to work early in treatment. That is expected and is not a reason to double the dose.

What the perioperative guidance adds

The clearest institutional statement about GLP-1 drugs and the stomach comes from perioperative medicine. A 2025 multi-society guidance in the British Journal of Anaesthesia set out how to manage patients on GLP-1 drugs around surgery, where retained stomach contents create a genuine aspiration risk under anesthesia ^[3]. It is not about NSAIDs, but it is the best evidence that the profession takes the gastric-emptying effect seriously enough to plan around it — and it reinforces that the effect is real, dose-related and most relevant when the stomach needs to be empty.

Practical guidance

• Take NSAIDs with food and a full glass of water. Standard advice, and it matters more when the stomach empties slowly.
• Use the lowest effective dose for the shortest time. The gastric risk is dose and duration dependent ^{[4] [5]}.
• Prefer acetaminophen for routine aches if it controls your symptoms, since it avoids the gastric risk entirely.
• Be extra careful in the first weeks after a dose increase, when the gastric-emptying effect is strongest ^[1].
• Tell your prescriber if you need an NSAID daily. Regular use may warrant a stomach-protecting medication, a decision that has nothing to do with the GLP-1 and everything to do with the NSAID.
• Do not stop a GLP-1 on your own to take ibuprofen. There is no interaction that requires it.